sicklecellanemianews1d
Etavopivat may reduce VOC rate, increase hemoglobin in SCD
Data from a Phase 2/3 trial shows etavopivat may reduce the incidence of vaso-occlusive crises and raise levels of hemoglobin ...
sicklecellanemianews5d
Why it’s important to celebrate good care when we receive it
Sickle cell patients often face challenges when implementing their care plans. Columnist Mary Shaniqua describes what good ...
sicklecellanemianews7d
The difficult reality of dealing with invisible sickle cell complications
Invisible complications of sickle cell disease can result in a lack of understanding and proper care, says columnist.
sicklecellanemianews13d
Kanglin raises $20M to advance sickle cell gene therapy KL003
Kanglin Biotechnology has raised $20 million in financing to advance the development of sickle cell gene therapy KL003.
sicklecellanemianews6d
Most patients free of vaso-occlusive crises for years after Casgevy dose
Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
sicklecellanemianews8d
Most SCD patients given Lyfgenia in trials stay free of VOEs: New data
The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...